RS51010B - Pripremanje nekristalinskog atorvastatin-kalcijuma - Google Patents
Pripremanje nekristalinskog atorvastatin-kalcijumaInfo
- Publication number
- RS51010B RS51010B YUP-568/03A YUP56803A RS51010B RS 51010 B RS51010 B RS 51010B YU P56803 A YUP56803 A YU P56803A RS 51010 B RS51010 B RS 51010B
- Authority
- RS
- Serbia
- Prior art keywords
- volume
- atorvastatin
- group
- dihydroxy
- protecting group
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 2
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
- 229960005370 atorvastatin Drugs 0.000 abstract 3
- 125000006239 protecting group Chemical group 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 238000010511 deprotection reaction Methods 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- MMCOUVMKNAHQOY-UHFFFAOYSA-N carbonoperoxoic acid Chemical group OOC(O)=O MMCOUVMKNAHQOY-UHFFFAOYSA-N 0.000 abstract 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Postupak za pripremanje atorvastatina u nekristalinskoj formi, naznačen time, što podrazumeva:a) obezbeđivanje rastvora koji sadrži intermedijarno jedinjenje koje ima sledeću formulu (I) u nehidroksilnom rastvaraču:gde A označava zajedničku protektivnu grupu ili zasebne protektivne grupe za dihidroksi grupu i B označava karbonsko-kiselinsku protektivnu grupu;b) sprovođenje deprotektovanja dihidroksi grupe;c) sprovođenje deprotektovanja karbonsko-kiselinske protektivne grupe; gde redosled koraka b) i c) može biti obrnut;d) koncentrovanje rastvora do približno polovine inicijalne zapremine ili manje;e) dodavanje vode u zapremini većoj od zapremine koncentrovanog rastvora;f) dodavanje približno iste ili veće zapremine nego stoje zapremina vode dodate u koraku e), rastavarača koji se slabo meša ili se ne meša sa vodom i u kome je atorvastatin-kalcijum nerastvorljiv ili praktično nerastvorljiv;g) po slobodnom izboru obavljanje operacije mešanja, i razdvajanje dve faze;h) neutralizovanje vodene faze;i) konvertovanje dihidroksi-karbonskokiselinske forme atorvastatina u farmaceutski prihvatljivu formu soli; ij) formiranje precipitata atorvastatina konvertovanog u pomenutu farmaceutski prihvatljivu formu soli.Prijava sadrži još 21 patentni zahtev.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200100010A SI20814A (sl) | 2001-01-23 | 2001-01-23 | Priprava amorfnega atorvastatina |
Publications (2)
Publication Number | Publication Date |
---|---|
YU56803A YU56803A (sh) | 2006-05-25 |
RS51010B true RS51010B (sr) | 2010-10-31 |
Family
ID=20432812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-568/03A RS51010B (sr) | 2001-01-23 | 2002-01-22 | Pripremanje nekristalinskog atorvastatin-kalcijuma |
Country Status (27)
Country | Link |
---|---|
US (2) | US6750353B2 (sr) |
EP (1) | EP1373202B1 (sr) |
JP (1) | JP4336106B2 (sr) |
KR (1) | KR100882066B1 (sr) |
CN (1) | CN1260213C (sr) |
AT (1) | ATE294159T1 (sr) |
AU (1) | AU2002219455B2 (sr) |
BG (1) | BG108017A (sr) |
BR (1) | BR0206637A (sr) |
CA (1) | CA2435954C (sr) |
CZ (1) | CZ20031988A3 (sr) |
DE (1) | DE60203894T2 (sr) |
DK (1) | DK1373202T3 (sr) |
EE (1) | EE05270B1 (sr) |
ES (1) | ES2240748T3 (sr) |
HR (1) | HRP20030575B1 (sr) |
HU (1) | HU227535B1 (sr) |
IL (2) | IL157068A0 (sr) |
MX (1) | MXPA03006548A (sr) |
PL (1) | PL209428B1 (sr) |
RS (1) | RS51010B (sr) |
RU (1) | RU2324679C2 (sr) |
SI (2) | SI20814A (sr) |
SK (1) | SK286593B6 (sr) |
UA (1) | UA73829C2 (sr) |
WO (1) | WO2002059087A1 (sr) |
ZA (1) | ZA200305307B (sr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
JP2004516311A (ja) | 2000-12-27 | 2004-06-03 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | アトルバスタチン結晶体 |
EP1365995A2 (en) * | 2001-02-27 | 2003-12-03 | Council of Scientific and Industrial Research | Essential oil composiiton for potable water disinfection |
EE200300597A (et) | 2001-06-29 | 2004-02-16 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid |
WO2005033078A1 (en) * | 2003-10-07 | 2005-04-14 | Biocon Limited | Process for the production of atorvastatin calcium |
HU227124B1 (en) * | 2001-09-14 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin |
KR20040086397A (ko) | 2002-02-19 | 2004-10-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
CA2520740C (en) * | 2003-04-11 | 2012-06-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
CA2530446A1 (en) | 2003-07-02 | 2005-01-13 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous form of a platelet aggregation inhibitor drug |
AU2003247327A1 (en) * | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
AU2004309313A1 (en) * | 2003-12-29 | 2005-07-14 | Lek Pharmaceuticals D.D. | Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
CA2666359A1 (en) | 2004-03-17 | 2005-10-06 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
EP3581564A1 (en) | 2004-05-05 | 2019-12-18 | Pfizer Products Inc. | Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
US8044086B2 (en) * | 2004-07-16 | 2011-10-25 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
CA2701710C (en) | 2004-07-20 | 2013-08-27 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
WO2006021969A1 (en) * | 2004-08-27 | 2006-03-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
EP1807055A1 (en) | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
ES2304335T3 (es) | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio. |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
EP1979313A1 (en) * | 2006-01-31 | 2008-10-15 | Jubilant Organosys Limited | Process for the preparation of amorphous atorvastatin calcium salt |
CN100406438C (zh) * | 2006-06-30 | 2008-07-30 | 浙江新东港药业股份有限公司 | 一种无定型阿伐他汀钙的制备方法 |
US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
CA2702903C (en) | 2007-10-17 | 2016-01-19 | Todd F. Ovokaitys | Process for the modification of the solid state of a compound and co-amorphous compositions produced with same |
WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium |
KR101050722B1 (ko) | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
HUE030160T2 (en) * | 2010-04-19 | 2017-05-29 | Dsm Sinochem Pharm Nl Bv | Preparation of atorvastatin with low dietary contamination |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
US10202598B2 (en) | 2014-05-30 | 2019-02-12 | Todd Frank Ovokaitys | Methods and systems for generation, use, and delivery of activated stem cells |
US10384985B2 (en) | 2014-06-06 | 2019-08-20 | B.K. Consultants, Inc. | Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants |
WO2015187974A1 (en) | 2014-06-06 | 2015-12-10 | Ovokaitys Todd Frank | Methods and compositions for increasing the bioactivity of nutrients |
CN113321607A (zh) * | 2020-02-28 | 2021-08-31 | 北京福元医药股份有限公司沧州分公司 | 一种阿托伐他汀钙中间体的纯化方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
EA000474B1 (ru) | 1995-07-17 | 1999-08-26 | Варнер-Ламберт Компани | Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин) |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
IN191236B (sr) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd |
-
2001
- 2001-01-23 SI SI200100010A patent/SI20814A/sl not_active IP Right Cessation
-
2002
- 2002-01-22 RS YUP-568/03A patent/RS51010B/sr unknown
- 2002-01-22 DE DE60203894T patent/DE60203894T2/de not_active Expired - Lifetime
- 2002-01-22 RU RU2003124962/04A patent/RU2324679C2/ru not_active IP Right Cessation
- 2002-01-22 CZ CZ20031988A patent/CZ20031988A3/cs unknown
- 2002-01-22 MX MXPA03006548A patent/MXPA03006548A/es active IP Right Grant
- 2002-01-22 AT AT02734878T patent/ATE294159T1/de active
- 2002-01-22 ES ES02734878T patent/ES2240748T3/es not_active Expired - Lifetime
- 2002-01-22 CN CNB028039688A patent/CN1260213C/zh not_active Expired - Fee Related
- 2002-01-22 SK SK908-2003A patent/SK286593B6/sk not_active IP Right Cessation
- 2002-01-22 JP JP2002559389A patent/JP4336106B2/ja not_active Expired - Fee Related
- 2002-01-22 EP EP02734878A patent/EP1373202B1/en not_active Expired - Lifetime
- 2002-01-22 BR BR0206637-8A patent/BR0206637A/pt not_active IP Right Cessation
- 2002-01-22 CA CA002435954A patent/CA2435954C/en not_active Expired - Fee Related
- 2002-01-22 UA UA2003076436A patent/UA73829C2/uk unknown
- 2002-01-22 KR KR1020037009509A patent/KR100882066B1/ko not_active IP Right Cessation
- 2002-01-22 IL IL15706802A patent/IL157068A0/xx unknown
- 2002-01-22 AU AU2002219455A patent/AU2002219455B2/en not_active Ceased
- 2002-01-22 WO PCT/IB2002/000161 patent/WO2002059087A1/en active IP Right Grant
- 2002-01-22 PL PL361763A patent/PL209428B1/pl unknown
- 2002-01-22 HU HU0302797A patent/HU227535B1/hu not_active IP Right Cessation
- 2002-01-22 EE EEP200300333A patent/EE05270B1/xx not_active IP Right Cessation
- 2002-01-22 DK DK02734878T patent/DK1373202T3/da active
- 2002-01-22 SI SI200230156T patent/SI1373202T1/sl unknown
- 2002-12-18 US US10/323,444 patent/US6750353B2/en not_active Expired - Fee Related
-
2003
- 2003-07-09 ZA ZA200305307A patent/ZA200305307B/xx unknown
- 2003-07-15 HR HR20030575A patent/HRP20030575B1/xx not_active IP Right Cessation
- 2003-07-22 BG BG108017A patent/BG108017A/bg unknown
- 2003-07-23 IL IL157068A patent/IL157068A/en not_active IP Right Cessation
- 2003-10-03 US US10/677,344 patent/US7074940B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51010B (sr) | Pripremanje nekristalinskog atorvastatin-kalcijuma | |
JP2005503997A5 (sr) | ||
ATE477238T1 (de) | Verfahren zur herstellung von dithioestern | |
ATE438704T1 (de) | Fluoridhaltige saure zusammensetzung zur entfernung von photolack- und ätzrückständen | |
BR0113494A (pt) | Processo para a preparação de uma formulação sólida herbicida, e, uso de uma formulação sólida herbicida | |
ATE302786T1 (de) | Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv | |
SI21463B (sl) | Postopek za pripravo heksahidro-furo/2,3-b/furan-3-ola | |
JP2003525287A5 (ja) | 1,3-ジヒドロ-2h-インドール-2-オンならびにアルギニン-バソプレッシンのv1bまたはv1bおよびv1aの両方のレセプターのリガンドとしてのそれらの使用 | |
ATE423778T1 (de) | Verfahren zur herstellung von anthranilsäurederivat-hydrat | |
BR0109048A (pt) | Processo para a sìntese de citalopram | |
DK0922066T3 (da) | Polymere fortykkelsesmidler til vandige sammensætninger | |
HRPK20040287B3 (en) | Process for the preparation of citalopram | |
ATE295716T1 (de) | Mittel und verfahren zu dauerhaften haarverformung auf basis von 2- mercaptopropionsäureamiden sowie verfahren zu deren herstellung | |
ATE345766T1 (de) | Topische zusammensetzungen mit einer äusseren ölphase und verfahren zu deren herstellung | |
DE69614096T2 (de) | Verfahren zur herstellung einer festen arzneimitteldosierungsform | |
DE50107377D1 (de) | Verfahren zur herstellung von 2-alkyl-3-aryl- und -heteroaryloxaziridinen und neue 2-alkyl-3-aryloxaziridine | |
KR920004332A (ko) | 수용액중의 l-포스피노트리신 및 l-글루탐산의 추출분리법 | |
ATE266635T1 (de) | Verfahren zur herstellung von zofenopril- calciumsalz | |
HUP0300738A2 (hu) | Eljárás LHRH hatású peptid-sók elżállítására, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
ATE236925T1 (de) | Verfahren zur reinigung von apolipoproteinen | |
DK1109782T3 (da) | Fremgangsmåde til fremstilling af N-beskyttede azetidin-2-carboxylsyrer (AzeOH'er) | |
KR840001121A (ko) | 데카복실라제- 저해제인 플루오르화 알칸디아민유도체의 제조방법 | |
KR940021524A (ko) | 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법 | |
ATE357429T1 (de) | Verfahren zur herstellung von beta- ketonitrilverbindungen | |
RU2077913C1 (ru) | Способ получения трехфазных экстракционных систем |